ABSTRACT
Introduction Tuberculosis (TB) is the leading cause of death in children living with HIV (CLHIV) and is challenging to confirm the diagnosis. The PAANTHER treatment decision algorithm (TDA) was developed to improve the diagnosis of TB in CLHIV. We aimed to externally validate the PAANTHER TDA in CLHIV with presumptive TB.
Methods We conducted a prospective diagnostic cohort study in seven tertiary hospitals across Côte d’Ivoire, Mozambique, Uganda, and Zambia, implementing the PAANTHER TDA in CLHIV aged between 1 month and 14 years with presumptive TB. TDA assessments included Xpert MTB/RIF Ultra (Ultra) on respiratory and stool samples, history of contact, symptoms (fever >2 weeks, unremitting cough, haemoptysis and/or weight loss in previous 4 weeks, tachycardia), chest radiography and abdominal ultrasound. A positive score (>100) prompted TB treatment initiation. Children were followed-up for 6 months, and retrospectively classified as having confirmed, unconfirmed or unlikely TB. The primary outcome was the proportion of missed TB cases (false negative) among children with negative scores; secondary outcomes included TDA diagnostic accuracy, feasibility, and time to treatment initiation. The TDA was considered validated if the negative predictive value (NPV, 1 - rate of false negative) was superior to a 75% pre-established confidence interval lower limit.
Findings From 2 October 2019 to 31 December 2021, we enrolled 277 CLHIV, including 175 (63·2%) who were on antiretroviral therapy at inclusion. 272 (98·2%) children had a complete TDA evaluation; 215 (75.8%) scored >100, including 24 (8·7%) with positive Ultra. 182 (86·7%) children who scored ≥100, and 12 children who scored negative, initiated TB treatment at a median of 1 (IQR: 0-3) and 27 [8·2; 64] days after inclusion, respectively. 62/215 children (28·8%) who scored ≥100 were classified as having unlikely TB and 4/12 (33·3%) who scored negative were initiated on treatment and were classified as having unconfirmed TB. The proportion of children with TB (confirmed and unconfirmed) was 155/273 (56·8%; 95% CI: 50·9; 62·5). The NPV was 55/67 (93·3%; 95% CI: 84·1; 97·4), reaching protocol-defined validation. The TDA sensitivity was 97·4% (95% CI: 93·6; 90·0) with specificity of 47·5 (95% CI: 38·7; 56·4).
Interpretation The PAANTHER TDA was validated in CLHIV. Its high sensitivity, excellent feasibility, and short turnaround time to treatment initiation, should allow rapid treatment decision-making and could reduce morbidity and mortality in CLHIV.
Funding UNITAID
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04121026
Clinical Protocols
https://www.tb-speed.com/wp-content/uploads/2022/08/TB-Speed-HIV-Study-Protocol.pdf
Funding Statement
This study was funded by UNITAID
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Comité d'Évaluation & Éthique de l'Inserm (CEEI Inserm) granted ethical approval for this work. The IRB of the WHO ERC granted ethical approval for this work. The Central Ethics Committee of the Comité National d'Éthique des Sciences de la Vie et de la Santé (CNEVS), Côte d'Ivoire, granted ethical approval for this work. The Central Ethics Committee - Comité Nacional de Bioética para a Saúde (CNBS), Mozambique, granted ethical approval for this work. The IRB of Mbarara University of Science and Technology (MUST) granted ethical approval for this work. The Central Ethics Committee of the Uganda National Council for Science and Technology (UNCST) granted ethical approval for this work. The IRB of the University of Zambia Biomedical Research Ethics Committee granted ethical approval for this work. The Central Ethics Committee of the National Health Research Authority (NHRA), Zambia, granted ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
